Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer
· prnewswire.com · popularity 18/100 · 0 similar stories today · Cancer & Oncology (Health & Life Sciences)
Read the original at prnewswire.com →
Summary
First-of-its-kind dual-antigen-targeted bispecific regimen of pasritamig and JNJ-9401 directed at two prostate cancer proteins, KLK2 and PSMA, using complementary signals to activate T cells against cancer Deep and sustained PSA responses observed with every-six-week dosing, with 73% (11...
Found in: PR Newswire. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 11.